The following biotech stocks reached a 52-week high on September 8, 2026, driven by a series of clinical developments and significant regulatory milestones.
Pharvaris N.V. (PHVS)
Pharvaris is a late-stage biopharmaceutical company dedicated to developing oral bradykinin B2 receptor antagonists for the treatment of bradykinin-mediated hereditary angioedema (HAE). The company’s stock rose over 7% to a 52-week high of $43.25 on Tuesday. While Pharvaris reported a net loss of EUR 47.8 million in the second quarter, up from EUR 45.5 million in the prior year, investor focus remained on its clinical pipeline. On Tuesday, the company announced positive topline results from the Phase 3 CHAPTER-3 trial for its lead drug, Deucrictibant, which decreased HAE attacks by 87% in treated patients. The U.S. Food and Drug Administration (FDA) accepted the NDA for deucrictibant in July 2026 and may provide a response by April 23, 2027.
Roivant Sciences Ltd. (ROIV)
Roivant Sciences is a commercial-stage biopharmaceutical company developing medicines targeting various autoimmune diseases. On Tuesday, shares climbed over 6% to a new 52-week high of $42.50 in intraday trading. Roivant reported positive topline results from the Phase 2 PHocus trial for Mosicliguat in treating pulmonary hypertension associated with interstitial lung disease (PH-ILD). The data indicates that the drug met the study’s primary endpoint and will now be evaluated in the global Phase 3 PHrontier trial. Additionally, the company received FDA approval for LISRAYA in the treatment of dermatomyositis last month.
BlossomHill Therapeutics Inc. (BLSM)
Blossom Hill Therapeutics is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for the treatment of rare cancers. Shares climbed over 4% to a 52-week high of $23.37 on Tuesday. The company began trading on the Nasdaq Global Select Market on August 7, 2026, earning approximately $150 million in an initial public offering (IPO). Earlier this month, BlossomHill received a Fast Track designation from the U.S. Food and Drug Administration (FDA) for BH-30643 in advanced or metastatic non-small cell lung cancer (NSCLC) as a Phase 1/2 study for the drug completes enrollment. BH-30643 is the company’s lead drug candidate and demonstrated effective inhibition of cancer cells with EGFR mutations in preclinical studies.
AtriCure Inc. (ATRC)
AtriCure provides various technologies to treat atrial fibrillation (Afib), an irregular heart rhythm originating in the upper heart chambers known as the atria. Shares reached a 52-week high of $55.72 on Tuesday. Among the company’s key products is the Isolator Synergy surgical ablation system, used to repair faulty atrial walls that cause Afib. The system was the first medical device for treating persistent Afib to receive FDA approval. Other treatments include the AtriClip left atrial appendage (LAA) exclusion system, the minimally invasive Hybrid AF therapy, and the cryoICE cryoSPHERE and cryoXT probes for temporary ablation to block peripheral nerve signaling. For the second quarter of this year, the company reported revenue of $153.6 million, reflecting 12.8% growth. Revenue for the full year of 2026 is estimated between $602 million and $610 million, considerably higher than the $534 million recorded last year.
Faeth Therapeutics Inc. (FTH)
Faeth Therapeutics is a clinical-stage biotechnology company focused on developing drugs that block oncogenic pathways using multi-node inhibition. Shares of Faeth Therapeutics touched a 52-week high of $42.14 during intraday trading on Tuesday. The company recorded a net loss of $16 million in the second quarter of 2026, compared to $4.9 million a year ago. The company is advancing the combination therapy PIKTOR for the treatment of HR+/HER- breast cancer in a Phase 1/2 trial, with interim data expected in 2027. The therapy is also being evaluated in a Phase 2 trial for endometrial cancer, with topline data expected in the second half of 2026.
This Day In History:
On this day in 1903, pharmacologist Marthe Vogt was born. The German-British scientist pioneered early research into neurotransmitters and their fundamental role in nerve signaling. After fleeing Nazi Germany, Vogt published a paper proving the function of acetylcholine in muscle movement and highlighted the importance of epinephrine and norepinephrine in brain cell communication. A number of modern anti-depressant therapies were formulated based on her findings.